Clinical Trial Update: Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating fulvestrant for recurrent or metastatic endometrial carcinoma has completed with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Carcinoma

Drugs mentioned

• Fulvestrant (fulvestrant)

Snippet

Sponsor: AstraZeneca | Conditions: Endometrial Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2012-07-31